Background: Retinopathy of prematurity (ROP) which is also known as retrolental fibroplasia is a vasoproliferative disorder that affects premature infants. Despite of major advancement in management, it continues to be a leading cause of childhood blindness throughout the world. As there had been very few studies conducted here and very few information regarding this disease are available we conducted this study. Aim of the study: The aim of this study was to evaluate the effect of supplemental Oxygen on development of retinopathy of prematurity. Methods: This was a prospective cohort study which was conducted at the Special Care Baby Unit (SCABU) and Intensive Care Unit (ICU) of Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh during the period from July 2012 to December 2014. In total One Hundred and Twenty (120) 0-28 day's old neonates of both sexes possibilities of ROP were finalized as the study population. Data were processed and analyzed using statistical software SPSS version 17, EPI info 7. Result: In this study, thirty (36.59%) neonates got oxygen up to 72 hours did not developed ROP. Only one 1(2.63%) ROP (+ve) neonates received oxygen for 73 to 120 hours. Those who received oxygen for duration of 170-218 hours and >218 hours developed ROP, RR was 2.01 [1.17-3.48] and 4.67 [2.71-8.03] respectively and (p<0.05). On the other hand, five neonates (13.16%) of ROP (+ve) got percentage of oxygen in inhaled air (41-60)% and this concentration was found statistically significant risk for ROP, RR 3.48 [2.61-4.64] but there was no risk associated with FiO2 (24-32)% or 33-40% in inhaled air. SpO2 (95-99) % was present in 29 (76.32%) of ROP (+ve) neonates and 19 (23.17%) in ROP (-ve) neonates. Conclusion: The practice of providing oxygen and blood transfusion are often lifesaving, a more judicious approach to the use of such therapies may help to reduce the problem of ROP. Inappropriate supplementation of oxygen may not correct hypoxia or may lead to hyperoxia. Both the conditions are injurious to neonatal health. During oxygen therapy, SpO2 value and more precisely the PaO2 value on neonate should be maintained within a target range. The finding of this study should be explored in the future.
Background: Retinopathy of prematurity (ROP) is a potentially blinding disease affecting the retinas in premature infants. In the treatment procedure of ROP, oxygen inhalation as well as the SpO2, PaO2, FiO2 levels analysis are some major concerns.Methods: This was a prospective COHORT study which was conducted at the special care baby unit (SCABU) and intensive care unit (ICU) of Dhaka shishu (children) hospital, Dhaka, Bangladesh from July 2012 to December 2014. Total one hundred (100) neonates of both sexes were finalized as the study population. Data were processed and analyzed using statistical software SPSS version 17, EPI info 7.Results: We found statistically significant risk for ROP, RR 3.48 (2.61-4.64) but there was no risk associated with FiO2 (24-32) % or 33-40 % in inhaled air. SpO2 (95-99) % was present in 25 (78.13%) of ROP (positive) neonates and 16 (23.53%) in ROP (negative) neonates. The difference was statistically significant (p<0.05) between the groups and RR 4.8 (2.51-9.28) for saturation of 95-99%. Partial pressure of oxygen >150 mm of Hg present in 12 (37.50%) cases of ROP (positive) neonates and 6 (8.82%) in ROP (negative) neonates. The difference was statistically significant (p<0.05) between the groups and RR 2.90 (1.83-4.5) for partial pressure of oxygen (>150) but there was no risk for partial pressure of 70-99 and 100-150 mm of Hg.Conclusions: During oxygen therapy FiO2 value, SpO2 value and more precisely the PaO2 value on neonate should be maintained within a target range.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.